RE "2017 revenue," doodling recently I noted,
The production guidance for 2017 given in the recent GXY presentation is (120 to 150) kt spodumene. The prices are being negotiated in Q4 2016. They will be at least $600/t and may be 20% higher (per Anthony Tse) ie $720/t
So the revenue in 2017 should be somewhere between $72 million (120 kt at $600/t) and $108 million (150 kt at $720/t)
With 1788 m shares (undiluted) this is 4 to 6 cents per share, or 12.5% to 18.5% of the current share value, 30.5 cents.
- Forums
- ASX - By Stock
- GXY
- General: Share Price, Trades and chart related discussions
General: Share Price, Trades and chart related discussions, page-1589
-
- There are more pages in this discussion • 1,735 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GXY (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online